Has Chin Kim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,615 in general payments to Chin Kim, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chin Kim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chin Kim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chin Kim, MD

Interventional Cardiology · Orlando, FLNPI 1437120896

Payments from drug & device makers

$8,615in general payments, 2019–2025

Across 5 payments — averaging $1723.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$9K
Medtronic$87
Daiichi Sankyo Inc.$16
Regeneron Healthcare Solutions, Inc.$12

What the payments were for

Food & beverage$10389%
Education$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	2	$8,500
Medtronic	1	$87
Daiichi Sankyo Inc.	1	$16
Regeneron Healthcare Solutions, Inc.	1	$12

How this compares

$8,615 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida →

Medicare billing

Part B allowed, 2024

$395,328

Medicare patients

692

Services billed

2,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	311	$367,312
XareltoRivaroxaban	35	$53,149
EntrestoSacubitril/Valsartan	26	$29,865
MultaqDronedarone Hcl	15	$25,491
Repatha SureclickEvolocumab	26	$24,149
Rosuvastatin Calcium	467	$6,189
Ranolazine ErRanolazine	28	$3,284
Metoprolol Succinate	267	$3,223
ClopidogrelClopidogrel Bisulfate	188	$2,524
Atorvastatin Calcium	262	$2,304
Ezetimibe	92	$2,042
Losartan Potassium	163	$1,938
Carvedilol	170	$1,681
Potassium Chloride	39	$1,271
Isosorbide Mononitrate ErIsosorbide Mononitrate	106	$1,261

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Orlando

Vijaykumar KasiOrlando$1.1M
Zahid AminOrlando$670K
Farhan KhawajaOrlando$636K
Dominick AngiolilloJacksonville$4M
Douglas SpriggsClearwater$3.2M
Rakesh PrashadOcala$3.1M
Aldo Martinez FleitesMiami Lakes$2.2M
Rohit AminPensacola$2M
Roberto CubedduNaples$2M
Arthur LeeGainesville$2M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →